1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Lykos’ MDMA Trial Conduct Allegations Influence US FDA Advisory Committee

 
• By Bridget Silverman

Safety concerns related to MDMA patient suggestibility and impairment troubled the panel reviewing psychedelic therapy for PTSD, although the FDA advised that therapist misconduct is outside its control.

psychotherapy
The FDA does not regulate psychotherapy. • Source: Shutterstock

Advisory committee members could not limit their review of Lykos’ proposed MDMA therapy for post-traumatic stress disorder to issues directly within the US Food and Drug Administration’s control, which could impact the agency’s final decision on the product.

Lykos’ proposed midomafetamine-assisted therapy (MDMA-AT) process poses a “novel treatment paradigm,” where the psychedelic drug is intended to catalyze effective...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 
• By Bridget Silverman

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.